MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: hepatocellular carcinoma
MedXY News
EnglishTag

hepatocellular carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
GastroenterologyChất ức chế kinase tyrosinehepatocellular carcinoma

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY|Jun 28, 2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
Gastroenterology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
hepatocellular carcinoma
immunotherapy

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY|Jun 27, 2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
Gastroenterologychronic hepatitis Bcirrhosis

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

By MedXY|Jun 10, 2026

In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice
Gastroenterologyhepatocellular carcinomaliver transplantation

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice

By MedXY|Jun 7, 2026

A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.

Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Gastroenterologydownstaginghepatocellular carcinoma

Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

By MedXY|Jun 3, 2026

Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results
Gastroenterologyabbreviated MRIcirrhosis

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results

By MedXY|May 13, 2026

A prospective trial found that non-contrast abbreviated MRI detected hepatocellular carcinoma in cirrhotic patients far better than ultrasound, with most MRI-detected tumors found at an early, potentially curable stage.

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma
Gastroenterologyatezolizumabbevacizumab

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma

By MedXY|May 10, 2026

A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i

Uncoupling Metabolic Reprogramming in Hepatocellular Carcinoma: The JOSD1-PGAM1 Ubiquitination-Lactylation Switch
Clinical UpdatesGlycolysishepatocellular carcinoma

Uncoupling Metabolic Reprogramming in Hepatocellular Carcinoma: The JOSD1-PGAM1 Ubiquitination-Lactylation Switch

By MedXY|May 1, 2026

This article explores how the deubiquitinase JOSD1 drives HCC progression by modulating a novel PTM switch on PGAM1, promoting glycolysis and immune evasion while providing a new target for combined immunotherapy.

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models
Gastroenterologycirrhosishepatocellular carcinoma

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models

By MedXY|Apr 23, 2026

The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Gastroenterologyablation therapyhepatocellular carcinoma

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

By MedXY|Apr 14, 2026

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma
newsartificial intelligenceComputational Pathology

Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma

By MedXY|Apr 9, 2026

Researchers have developed an AI-powered framework that uncovers a non-linear relationship between tumor-stroma ratio and mortality in hepatocellular carcinoma, using a novel token-guided multimodal fusion approach to improve prognostic acc

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer
Gastroenterologybiomarkersgut-liver axis

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

By MedXY|Apr 6, 2026

A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease

Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy
Gastroenterologyfusion modelhepatocellular carcinoma

Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy

By MedXY|Apr 2, 2026

A groundbreaking multicentre study develops a clinical-radiologic model integrating hypoxia and immune phenotype signatures to accurately predict prognosis in hepatocellular carcinoma patients treated with transarterial chemoembolisation, p

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis
Clinical Updatesdeep learninghepatocellular carcinoma

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

By MedXY|Mar 15, 2026

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Gastroenterologyhepatocellular carcinomaimmunotherapy

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

By MedXY|Mar 12, 2026

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial
Gastroenterologyhepatocellular carcinomaHIMALAYA Trial

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY|Mar 11, 2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer
Clinical Updates8q24.12 Amplificationhepatocellular carcinoma

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer

By MedXY|Mar 10, 2026

This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling
Gastroenterologyhepatocellular carcinomaliquid biopsy

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY|Mar 8, 2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
Gastroenterologyantiviral prophylaxishepatocellular carcinoma

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY|Jan 12, 2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma
newshepatocellular carcinomaimmunotherapy

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma

By MedXY|Dec 14, 2025

A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models